Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Hodgkin Disease 1Alveolar Childhood Rhabdomyosarcoma 1

Interventions

Peripheral Blood Stem Cell Transplantation 5fludarabine phosphate 4Radiotherapy 4Antilymphocyte Serum 4Vincristine 3Vinblastine 3Procarbazine 3Prednisolone 3Methylprednisolone 3Melphalan 3Filgrastim 3Doxorubicin 3Cyclophosphamide 3Chlorambucil 3Busulfan 3Bortezomib 3Bevacizumab 3tipifarnib 2Vorinostat 2Sorafenib 2Oxaliplatin 2Mycophenolic Acid 2Methotrexate 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Etoposide 2Dacarbazine 2Cyclosporine 2Bleomycin 2Biopsy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Recurrence × indolepropanol phosphate × Clear all
NCT00381940 2021-03-24

Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy

National Cancer Institute (NCI)

Phase 2 Completed
26 enrolled 14 charts
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡